Suggested remit: To appraise the clinical and cost effectiveness of encorafenib with binimetinib within its marketing authorisation for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer (NSCLC).
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6177
Provisional Schedule
- Committee meeting: 2:
- 09 September 2025
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Pierre-Fabre (encorafenib and binimetinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Oncogene Cancer Research
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- Merck Sharpe & Dohme (pembrolizumab) (confidentiality agreement signed, participating)
- Novartis Pharmaceuticals (dabrafenib, trametinib) (confidentiality agreement signed, participating)
- Boehringer Ingelheim (nintedanib) (confidentiality agreement not signed, not participating)
- Bristol Myers Squibb (nivolumab) (confidentiality agreement not signed, not participating)
- Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine) (confidentiality agreement not signed, not participating)
- Medac (vinorelbine) (confidentiality agreement not signed, not participating)
- Pierre-Fabre (vinorelbine) (confidentiality agreement not signed, not participating)
- Ranbaxy [A Sun Pharmaceutical Company] (gemcitabine) (confidentiality agreement not signed, not participating)
- Roche (atezolizumab) (confidentiality agreement not signed, not participating)
- Sandoz (cisplatin) (confidentiality agreement not signed, not participating)
- Seacross Pharmaceuticals (docetaxel) (confidentiality agreement not signed, not participating)
- Synchrony Pharma (gemcitabine) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 June 2025 - 24 June 2025 | Draft guidance: 1 |
| 13 May 2025 | Committee meeting |
| 01 October 2024 | Invitation to participate |
| 28 June 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early October 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 24 May 2024 - 24 June 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6177 |
| 24 May 2024 | In progress. Scoping commencing |
| 03 July 2023 | Please note that following on from an update received from the company, appraisal has been scheduled into the work programme. The appraisal is now anticipated to begin during mid-July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2024. |
| 12 September 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual